← All trials
NCT06415773
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2024
- Primary completion
- Jul 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- May 16, 2024
- Last posted
- May 16, 2024
- Enrollment
- 418
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HighTide Biopharma Pty LtdLead sponsor
- HighTide Biopharma Pty LtdOfficial
- HighTide Biopharma Pty LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.